International Review of Ophthalmology ›› 2022, Vol. 46 ›› Issue (4): 318-323.doi: 10.3760/cma.j.issn.1673-5803.2022.04.005

Previous Articles     Next Articles

Mechanism and clinical application of tacrolimus in treatment of dry eye disease

Zhang Zijie, Jia Zhe, Zhao Shaozhen   

  1. Tianjin Key Laboratory of Retinal Functions and Diseases, Tianjin Branch of National Clinical Research Center for Ocular Disease, Eye Institute and School of Optometry, Tianjin Medical University Eye Hospital, Tianjin 300000, China

  • Received:2021-12-24 Online:2022-08-22 Published:2022-08-22
  • Contact: Zhao Shaozhen, Email: zhaosz1997@sina.com
  • Supported by:
    Youth Project of Health Commission of Tianjin Binhai New Area (2019BWKQ034); Clinical Key Discipline Project of Tianjin (TJLCZDXKT002)

Abstract: Dry eye disease (DED) is widely believed that immune-related inflammation plays an important role in its pathogenesis. Tacrolimus (FK506) has a certain therapeutic effect on ocular inflammation in dry eye by inhibiting calcineurin or MAPK pathway in T lymphocytes, NF-κB pathway in ocular surface cells, and apoptosis of ocular surface cells. Currently, studies on the topical use of tacrolimus in the treatment of dry eye have focused on dry eye with systemic immune diseases, including chronic graft-versus-host disease, Sjgren's syndrome, cicatoid pemphigoid, Steven-Johnson syndrome, etc.(Int Rev Ophthalmol, 2022, 46:  318-323)


Key words: dry eye disease, tacrolimus